kabutan

DAIICHI SANKYO COMPANY, LIMITED(4568) Summary

4568
TSE Prime
DAIICHI SANKYO COMPANY, LIMITED
3,478.0
JPY
-94.0
(-2.63%)
Dec 5, 11:30 am JST
22.42
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
3,480.9
Dec 5, 11:29 am JST
Summary Chart Historical News Financial Result
PER
22.3
PBR
3.90
Yield
2.24%
Margin Trading Ratio
13.74
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
3,512.0 JPY 22.63 USD
Previous Close Dec 4
3,572.0 JPY 22.99 USD
High Dec 5, 9:00 am
3,534.0 JPY 22.77 USD
Low Dec 5, 10:53 am
3,469.0 JPY 22.37 USD
Volume
3,220,600
Trading Value
0.01T JPY 0.07B USD
VWAP
3496.52 JPY 22.55 USD
Minimum Trading Value
347,800 JPY 2,242 USD
Market Cap
6.59T JPY 0.04T USD
Number of Trades
4,669
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
High
1-Year Average
9,108
1-Year High Apr 25, 2025
29,113
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 152,600 2,863,900 18.77
Nov 21, 2025 124,500 2,941,400 23.63
Nov 14, 2025 103,000 3,504,300 34.02
Nov 7, 2025 88,100 3,555,500 40.36
Oct 31, 2025 141,000 2,549,900 18.08
Company Profile
DAIICHI SANKYO COMPANY, LIMITED is a major pharmaceutical company in Japan, with strengths in cardiovascular and infectious diseases. The company has partnered with AstraZeneca of the UK for new cancer drugs.
Sector
Pharmaceuticals
DAIICHI SANKYO COMPANY, LIMITED primarily engages in the research, development, manufacturing, and sales of pharmaceuticals, with a broad range of operations both domestically and internationally. In Japan, the company operates through multiple subsidiaries involved in pharmaceutical manufacturing, research and development and sales of over-the-counter drugs, and vaccine research, development, and production, showcasing a diverse group of companies with varied functions. The company has partnered with AstraZeneca in the oncology field. Internationally, DAIICHI SANKYO has subsidiaries in the United States, Europe, China, Brazil, and other regions, conducting pharmaceutical research, development, manufacturing, and sales in each area. In the United States, the company has established a holding company, while in Europe, it operates through numerous group companies across various countries. DAIICHI SANKYO leverages its global network for research, development, manufacturing, and sales to enhance its competitiveness in the world market.